RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ono Pharmaceutical Co Stock

Ono Pharmaceutical Co ROA 2024

Ono Pharmaceutical Co ROA

0.14

Ticker

4528.T

ISIN

JP3197600004

WKN

859650

In 2024, Ono Pharmaceutical Co's return on assets (ROA) was 0.14, a 28.59% increase from the 0.11 ROA in the previous year.

Ono Pharmaceutical Co Aktienanalyse

What does Ono Pharmaceutical Co do?

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Ono Pharmaceutical Co's Return on Assets (ROA)

Ono Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Ono Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Ono Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Ono Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Ono Pharmaceutical Co stock

What is the Return on Assets (ROA) of Ono Pharmaceutical Co this year?

The Return on Assets (ROA) of Ono Pharmaceutical Co is 0.14 undefined this year.

What was the ROA of Ono Pharmaceutical Co compared to the previous year?

The ROA of Ono Pharmaceutical Co has increased by 28.59% compared to the previous year.

What consequences do high ROA have for investors of Ono Pharmaceutical Co?

A high ROA is advantageous for investors of Ono Pharmaceutical Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Ono Pharmaceutical Co?

A low ROA can be unfavorable for investors of Ono Pharmaceutical Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Ono Pharmaceutical Co affect the company?

An increase in ROA of Ono Pharmaceutical Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Ono Pharmaceutical Co impact the company?

A reduction in the ROA of Ono Pharmaceutical Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Ono Pharmaceutical Co?

Some factors that can influence the ROA of Ono Pharmaceutical Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Ono Pharmaceutical Co important for investors?

The ROA of Ono Pharmaceutical Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Ono Pharmaceutical Co take to improve ROA?

To improve ROA, Ono Pharmaceutical Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 4.88 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 4.88 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 5.26 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.